Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | PDE6D | O43924 | 1/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201984 | 0.86 | GABRA1 (0.49) | KCNK13ALDH1A1KDM4EP2RX7 | |
| SCHEMBL5203544 | 0.86 | TLR8 (0.41) | TP53KCNK13ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5204121 | 0.85 | TP53 (0.44) | TNFTP53KCNK13ALDH1A1MAPT | |
| SCHEMBL5204479 | 0.84 | MAPT (0.46) | TP53KCNK13ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5202670 | 0.84 | TLR8 (0.39) | TP53KCNK13ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29829358 | 0.83 | ALDH1A1 (0.63) | ESR1TNFTP53ALDH1A1PDE6D | |
| SCHEMBL5200958 | 0.82 | ALDH1A1 (0.66) | TNFTP53ALDH1A1PDE6DALDH2 | |
| SCHEMBL29830051 | 0.80 | TP53 (0.60) | ESR1TNFTP53ALDH1A1PDE6D | |
| SCHEMBL5204131 | 0.79 | TLR8 (0.38) | ESR1TP53KCNK13ALDH1A1ALDH2 | |
| SCHEMBL29829695 | 0.78 | ALDH1A1 (0.54) | ESR1TNFTP53KCNK13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210336-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US HEALTH (US) | 2007-04-25 | — | — | EP | disclosed |
| US-6894068-B2 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | MICHEJDA CHRISTOPHER J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-0963371-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US GOV HEALTH & HUMAN SERV (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6369235-B1 | INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-09 | — | — | US | disclosed |
| EP-0963371-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998037072-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | SAMHD1, DUT, TYMP | ESR1 2143/4885TNF 3481/4885TP53 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.